Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab versus ipilimumab in advanced melanoma
NL-OMON44956Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2013
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab and ipilimumab in melanoma (3 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Started Dec 2013; status: active, not recruiting.
02
Drugs
pembrolizumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON44956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44956.